CalciMedica reports Q3 2026 financial results and updates on PH program
The company reported $13.8M in cash and expects funding into H2 2027. The company plans to release Auxora Phase 1b data and an IND submission in mid-2027. Preclinical data suggests a differentiated approach in pulmonary hypertension.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
START FREE — 10,000 calls/day, no key needed